[Proton and neutron radiation in cancer treatment: clinical and economic outcomes].
The French National Agency for Medical Evaluation (ANDEM) was requested to assess the effectiveness of proton and neutron beam therapy in cancer treatment compared to conventional radiotherapy. This task was accomplished by a critical appraisal of the clinical and economic literature. According to the published economic literature and the capital and staffing cost analysis, it appears that the costs of proton therapy are likely to be two or three times greater than those of photon conformal therapy. According to the published clinical literature, proton beam therapy should be proposed as a routine treatment only for uveal melanoma and skull base cancers. Neutron beam therapy should be proposed as a routine treatment for inoperable salivary gland tumors; its use may be also discussed in cases of stage C-D1 prostate cancers and soft tissue sarcomas. Based on the current scientific evidence and given the incidence rate of these tumors, the time and material requirements, the current French proton/neutron beam facilities are able to meet the current demand. For other cancers the medical and economic potential of proton therapy is still an open question.
Fleurette
F
F
ANDEM, Paris, France.
Charvet-Protat
S
S
D003362:Cost-Benefit Analysis; D005069:Evaluation Studies as Topic; D006801:Humans; D008485:Medical Audit; D009369:Neoplasms / Q000532:radiotherapy*; D009502:Neutrons; D011216:Practice Management, Medical; D011522:Protons; D011882:Radiotherapy, High-Energy
D011522:Protons